{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Andrew", "organization": "", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [{"type": "image", "url": "images/2016/04/26/business/26MUSCLE/26MUSCLE-thumbWide.jpg", "legacy": {"wide": "images/2016/04/26/business/26MUSCLE/26MUSCLE-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/04/26/business/26MUSCLE/26MUSCLE-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/26/business/26MUSCLE/26MUSCLE-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "569"}, "width": 600, "subtype": "xlarge", "height": 569}, {"type": "image", "url": "images/2016/04/26/business/26MUSCLE/26MUSCLE-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/26/business/26MUSCLE/26MUSCLE-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"print_headline": "F.D.A. Advisers Rebuff Muscular Dystrophy Drug", "main": "Advisers to F.D.A. Vote Against Duchenne Muscular Dystrophy Drug"}, "print_page": "1", "keywords": [{"value": "Muscular Dystrophy", "is_major": "Y", "rank": "1", "name": "subject"}, {"value": "Food and Drug Administration", "is_major": "Y", "rank": "2", "name": "organizations"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "3", "name": "subject"}, {"value": "Clinical Trials", "is_major": "N", "rank": "4", "name": "subject"}, {"value": "Sarepta Therapeutics Inc.", "is_major": "N", "rank": "5", "name": "organizations"}], "snippet": "The staff of the F.D.A. said a clinical trial for the drug was too small, but advocates said the drug prolonged patients\u2019 ability to walk.", "source": "The New York Times", "lead_paragraph": "The staff of the F.D.A. said a clinical trial for the drug was too small, but advocates said the drug prolonged patients\u2019 ability to walk.", "word_count": "1256", "pub_date": "2016-04-26T00:00:00Z", "subsection_name": null, "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/04/26/business/muscular-dystrophy-drug-fda-sarepta-eteplirsen.html", "_id": "571e806e38f0d866887370f9"}